The US FTC files a complaint against an undertaking seeking permanent injunctive relief and equitable relief, including monetary relief, for an anticompetitive scheme to preserve a monopoly for a drug (Vyera Pharmaceuticals / Pharma Bro)

WILL THE SUPREME COURT LIMIT THE FTC’S USE OF SECTION 13(B) COURT ACTIONS?* The FTC’s authority to seek permanent injunctive relief and monetary relief under Section 13(b) of the FTC Act is being called into question. While more commonly used in consumer protection cases, Section 13(b) has been used by the FTC to seek injunctive relief and equitable relief in competition cases as well. Just this week, the FTC filed an antitrust complaint pursuant to Section 13(b) against Vyera Pharmaceuticals, LLC and “Pharma Bro” Martin Shkreli, seeking permanent injunctive relief and equitable relief, including monetary relief, for an alleged elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. Whether the FTC will be able to continue this practice is being

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Wolters Kluwer (Riverwoods)

Quotation

Jeffrey May, The US FTC files a complaint against an undertaking seeking permanent injunctive relief and equitable relief, including monetary relief, for an anticompetitive scheme to preserve a monopoly for a drug (Vyera Pharmaceuticals / Pharma Bro), 27 January 2020, e-Competitions January 2020, Art. N° 93237

Visites 250

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues